New drug SR-878 enters human testing for rheumatoid arthritis
NCT ID NCT07433335
First seen Mar 02, 2026 · Last updated May 23, 2026 · Updated 13 times
Summary
This early-stage study tests a new medicine, SR-878, in 27 adults with rheumatoid arthritis. The goal is to find a safe dose by checking for side effects. Participants will take the drug and be monitored for about 16 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
SciRhom clinical trial site
RECRUITINGTbilisi, Georgia
-
SciRhom clinical trial site
RECRUITINGChisinau, Moldova
-
SciRhom clinical trial site
RECRUITINGBucharest, Romania
-
SciRhom clinical trial site
RECRUITINGCluj-Napoca, Romania
Conditions
Explore the condition pages connected to this study.